Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Research on the Role of SLC1A5 in the Development of Esophageal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02633436
Recruitment Status : Unknown
Verified August 2016 by Fourth Affiliated Hospital of Guangxi Medical University.
Recruitment status was:  Recruiting
First Posted : December 17, 2015
Last Update Posted : August 12, 2016
Sponsor:
Collaborator:
Liuzhou Maternity and Child Healthcare Hospital
Information provided by (Responsible Party):
Fourth Affiliated Hospital of Guangxi Medical University

Brief Summary:
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Condition or disease Intervention/treatment
Esophageal Cancer Amino Acid Transport Disorder Other: SLC1A5 expression

Detailed Description:

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Official Title: Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer
Study Start Date : December 2015
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : August 2018


Group/Cohort Intervention/treatment
cancer tissues
SLC1A5 expression of esophageal cancer tissues from patients
Other: SLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

paired adjacent tissues
SLC1A5 expression of paired adjacent esophageal tissues from patients
Other: SLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.




Primary Outcome Measures :
  1. optical density (ODs) of each slice by immunohistochemistry assay [ Time Frame: within one year (plus or minus 1 month) after surgery ]
    For immunohistochemistry assay: Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.


Secondary Outcome Measures :
  1. SLC1A5 expression detected by WesternBlot [ Time Frame: within one year (plus or minus 1 month) after surgery ]
    Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis.


Biospecimen Retention:   Samples With DNA
Tissue specimens of esophageal cancer patients will be collected and stored in liquid nitrogen after operations


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with histologically proven esophageal cancer
Criteria

Inclusion Criteria:

  1. Patients with histologically proven esophageal cancer;
  2. Age ≥18 years;
  3. All patients must sign consent forms voluntarily;

Exclusion Criteria:

  1. Inability to obtain histologic proof of malignancy.
  2. Age <18 years;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02633436


Contacts
Layout table for location contacts
Contact: Shengming Dai, Dr. +86 13978026884 daishm@sina.com
Contact: Zheng Peng +86 18589966550 labstar@qq.com

Locations
Layout table for location information
China, Guangxi
Liuzhou Maternity and Child Healthcare Hospital Recruiting
Liuzhou, Guangxi, China, 545000
Contact: Xiaolan Lv    +86 15577727711    13505525@qq.com   
The Fourth Affiliated Hospital of Guangxi Medical University Recruiting
Liuzhou, Guangxi, China, 545000
Contact: Zheng Peng    +86 18589966550    labstar@qq.com   
Sponsors and Collaborators
Fourth Affiliated Hospital of Guangxi Medical University
Liuzhou Maternity and Child Healthcare Hospital
Investigators
Layout table for investigator information
Principal Investigator: Xiangcheng Wei Guangxi Medical University Institutional Review Board

Layout table for additonal information
Responsible Party: Fourth Affiliated Hospital of Guangxi Medical University
ClinicalTrials.gov Identifier: NCT02633436     History of Changes
Other Study ID Numbers: PJK201518
First Posted: December 17, 2015    Key Record Dates
Last Update Posted: August 12, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Fourth Affiliated Hospital of Guangxi Medical University:
esophageal cancer
SLC1A5

Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Amino Acid Metabolism, Inborn Errors
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases